title: Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties.
abstract: CD20 is a widely validated, B cell-specific target for therapy in B cell malignancies. Rituximab is an anti-CD20 Ab that prolongs survival of chronic lymphocytic leukemia (CLL) patients when combined with chemotherapy. Ofatumumab and GA101 (obinutuzumab) are CD20-directed Abs currently being developed as alternative agents to rituximab in CLL based upon different properties of enhanced direct cell death, NK cell-mediated Ab-dependent cellular cytotoxicity, or complement-dependent cytotoxicity. Despite widespread study, ofatumumab and GA101 have not been compared with each other, nor studied for their interactions with monocytes and macrophages which are critical for the efficacy of anti-CD20 Abs in murine models. In CLL cells, we show that direct cell death and complement-dependent cytotoxicity are greatest with GA101 and ofatumumab, respectively. GA101 promotes enhanced NK cell activation and Ab-dependent cellular cytotoxicity at high Ab concentrations. Ofatumumab elicits superior Ab-dependent cellular phagocytosis with monocyte-derived macrophages. GA101 demonstrated reduced activation of monocytes with diminished pERK, TNF-α release, and FcγRIIa recruitment to lipid rafts. These data demonstrate that GA101 and ofatumumab are both superior to rituximab against CLL cells via different mechanisms of potential tumor elimination. These findings bear relevance to potential combination strategies with each of these anti-CD20 Abs in the treatment of CLL.
authors: Integrated Biomedical Science Graduate Program, The Ohio State University, Columbus, OH 43210, USA.
authors: Sarwish
authors: S
authors: Rafiq
authors: Jonathan P
authors: JP
authors: Butchar
authors: Carolyn
authors: C
authors: Cheney
authors: Xiaokui
authors: X
authors: Mo
authors: Rossana
authors: R
authors: Trotta
authors: Michael
authors: M
authors: Caligiuri
authors: David
authors: D
authors: Jarjoura
authors: Susheela
authors: S
authors: Tridandapani
authors: Natarajan
authors: N
authors: Muthusamy
authors: John C
authors: JC
authors: Byrd
mesh_terms: D000912:Antibodies, Neoplasm / Q000627:therapeutic use / Q000633:toxicity*; D018951:Antigens, CD20 / Q000276:immunology* / Q000378:metabolism; D045744:Cell Line, Tumor; D003601:Cytotoxicity Tests, Immunologic; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D008264:Macrophages / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D009000:Monocytes / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D014407:Tumor Cells, Cultured
chemical_list: D000912:Antibodies, Neoplasm; D018951:Antigens, CD20